<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>In situ antigen–exposed priming under neoadjuvant checkpoint blockade produces broader, earlier, and more durable systemic immunity than adjuvant-only therapy - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Theory Details for theory-23</h1>

        <div class="section">
            <h2>Theory (General Information)</h2>
            <div class="info-section">
                <p><strong>ID:</strong> theory-23</p>
                <p><strong>Name:</strong> In situ antigen–exposed priming under neoadjuvant checkpoint blockade produces broader, earlier, and more durable systemic immunity than adjuvant-only therapy</p>
                <p><strong>Type:</strong> general</p>
                <p><strong>Theory Query:</strong> Build a theory of why neoadjuvant-plus-adjuvant immunotherapy improves melanoma outcomes compared to adjuvant-only immunotherapy, based on the following results.</p>
                <p><strong>Description:</strong> When immune checkpoint blockade (ICB) is initiated while the intact macroscopic tumor is still present, tumor-resident and draining-node antigen-presenting cells and tissue-resident memory T cells (TRM) are engaged in an antigen-rich context that drives early systemic activation, clonal expansion, and antigen spreading. This in situ priming before resection produces more robust control of micrometastatic disease and improves event-free survival relative to starting identical therapy only after surgery.</p>
                <p><strong>Knowledge Cutoff Year:</strong> 2029</p>
                <p><strong>Knowledge Cutoff Month:</strong> 12</p>
                <p><strong>Base Model:</strong> openai/gpt-5</p>
            </div>
        </div>
        </div>

        <div class="section">
            <h2>Theory (Statement/Laws)</h2>

            <h3>Theory Statements/Laws</h3>
            <hr/>
            <h3>Statement 0: Law 0</h3>
            <p><strong>Statement:</strong> None</p>
            <p><strong>Domain/Scope:</strong> <span class="empty-note">Not specified.</span></p>
            <h4>Special Cases</h4>
            <h4>Supporting Evidence for this Law</h4>
<p class="empty-note">No evidence provided.</p>            <h4>Self-Evaluation of Law Novelty (produced by the generation model)</h4>
            <p><strong>Likely Classification:</strong> unknown</p>
        <p><strong>Explanation:</strong> No explanation provided.</p>
        <p><strong>References:</strong> <span class="empty-note">No references provided.</span>            <h4>External Evaluations of this Law</h4>
            <p><strong>Predictive Accuracy Evaluation:</strong> <span class="empty-note">Not available.</span></p>
            <p><strong>Novelty Evaluation:</strong> <span class="empty-note">Not available (available only for a randomly selected subset of 100 laws, due to cost).</span></p>
            <hr/>
            <h3>Statement 1: Law 1</h3>
            <p><strong>Statement:</strong> None</p>
            <p><strong>Domain/Scope:</strong> <span class="empty-note">Not specified.</span></p>
            <h4>Special Cases</h4>
            <h4>Supporting Evidence for this Law</h4>
<p class="empty-note">No evidence provided.</p>            <h4>Self-Evaluation of Law Novelty (produced by the generation model)</h4>
            <p><strong>Likely Classification:</strong> unknown</p>
        <p><strong>Explanation:</strong> No explanation provided.</p>
        <p><strong>References:</strong> <span class="empty-note">No references provided.</span>            <h4>External Evaluations of this Law</h4>
            <p><strong>Predictive Accuracy Evaluation:</strong> <span class="empty-note">Not available.</span></p>
            <p><strong>Novelty Evaluation:</strong> <span class="empty-note">Not available (available only for a randomly selected subset of 100 laws, due to cost).</span></p>
            <hr/>
        </div>
        <div class="section">
            <h2>Theory (Additional Details)</h2>
                        <h3>New Predictions (Likely outcome)</h3>
            <ol>
                <li>Early on-treatment blood immune signatures after 1–2 neoadjuvant PD-1 doses (e.g., activated T-cell modules) will correlate with improved EFS beyond adjuvant-only baselines.</li>
                <li>Neoadjuvant PD-1 with concurrent agents that expand intratumoral T cells (e.g., LAG-3 blockade) will increase MPR and reduce early distant events versus adjuvant-only regimens.</li>
            </ol>
            <h3>New Predictions (Unknown outcome/high-entropy)</h3>
            <ol>
                <li>Augmenting neoadjuvant PD-1 with in situ vaccination (e.g., intratumoral TLR agonist) will further improve EFS by amplifying antigen spreading, but safety trade-offs are uncertain.</li>
                <li>Shortening the neoadjuvant window to a single PD-1 dose will retain most of the EFS advantage if robust early systemic activation occurs; magnitude unclear.</li>
            </ol>
            <h3>Negative Experiments</h3>
            <ol>
                <li>If randomized trials matching total PD-1 exposure show no EFS difference between neoadjuvant+adjuvant versus adjuvant-only, the timing advantage would be refuted.</li>
                <li>If serial sampling shows no early systemic activation (blood or TCR expansion) during neoadjuvant PD-1 despite improved EFS, mechanistic linkage to in situ priming would be weakened.</li>
            </ol>
            <h3>Unaccounted for Evidence</h3>
<ol>
    <li>Magnitude of benefit and optimal regimens in mucosal melanoma remain uncertain; some series show modest responses. <a href="../results/extraction-result-72.html#e72.6" class="evidence-link">[e72.6]</a> <a href="../results/extraction-result-72.html#e72.4" class="evidence-link">[e72.4]</a> <a href="../results/extraction-result-72.html#e72.1" class="evidence-link">[e72.1]</a> <a href="../results/extraction-result-72.html#e72.0" class="evidence-link">[e72.0]</a> <a href="../results/extraction-result-14.html#e14.3" class="evidence-link">[e14.3]</a> </li>
</ol>        </div>        <div style="height: 30px;"></div>
    </div>
</body>
</html>